Finerenone and Cardiac Remodeling

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 156 participants.

Also called NCT07270367

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 156 participants (planned count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as a collaborator
Registry
  • NCT NCT07270367
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07270367. Randomized; quadruple masking; primary purpose treatment. Start 2025-12 (anticipated); primary completion 2030-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Finerenone and Cardiac Remodeling
Acronym
FINE-MECH
Condition
Heart Failure
Intervention (Drug)
Finerenone
Intervention (Drug)
Placebo
Lead sponsor
Subodh Verma (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct07270367
Content hash
ef21b8c9e3f36b46da1ca2be5200d07073e4b5f0a2c2128e60a1d3565adce9e6